In vitro susceptibility of anaerobes to quinolones in the United States

Clinical Infectious Diseases

Volumn 23, Issue SUPPL. 1, 1996, Pages

  Hecht, David W ^a   Wexler, Hannah M ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINAFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; TROVAFLOXACIN;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEROIDES FRAGILIS; CLOSTRIDIUM PERFRINGENS; DRUG EFFICACY; FUSOBACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOSTREPTOCOCCUS; PREVOTELLA; PRIORITY JOURNAL; UNITED STATES;

EID: 0029807636     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.supplement_1.s2     Document Type: Article

References (11)

1. Hecht DW, Osmolski JR, O'Keefe JP. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals. Clin Infect Dis 1993; 16(suppl 4):S357-60.
2. Snydman DR, Cuchural GJ. Susceptibility variations in Bacteroides fragilis: a national survey. Infect Dis Clin Practice 1994;3:S34-43.
3. Goldstein EJC. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States. Clin Infect Dis 1993; 16(suppl 4):S377-81.
4. National Committee for Clinical Laboratory Standards. Methods for anti-microbial susceptibility testing of anaerobic bacteria: approved standard. 3rd ed. NCCLS document M11-A3. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1993.
5. Goldstein EJC, Citron DM. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother 1992;36:1158-62.
6. Chin NX, Gu JW, Yu KW, Zhang YX, Neu HC. In vitro activity of sparfloxacin. Antimicrob Agents Chemother 1991;35:567-71.
7. Fu KP, Lafredo SC, Foleno B, et al. In vitro and in vivo antibacterial activities of levofloxacin (I-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992; 36:860-6.
8. Sato K, Hoshino K, Tanaka M, Hayakawa I, Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother 1992;36:1491-8.
9. Kato N, Watanabe K, Kato H, Tanaka K, Tanaka Y, Ueno K. Comparative in vitro activity of DU-6859a, a new quinolone, against anaerobic bacteria [abstract 990]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1993:300.
10. Goldstein EJC, Nesbit CA, Citron DM. Comparative in vitro activities of azithromycin, Bay Y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates. Antimicrob Agents Chemother 1995;39:1097-100.
11. Barry AL, Fuchs PC. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother 1991;35: 955-60.